170,682 Shares in Stryker Corporation $SYK Acquired by Korea Investment CORP

Korea Investment CORP bought a new position in Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 170,682 shares of the medical technology company’s stock, valued at approximately $53,738,000.

Several other large investors have also recently bought and sold shares of the company. Sankala Group LLC purchased a new position in Stryker during the fourth quarter worth about $26,000. Godfrey Financial Associates Inc. bought a new position in Stryker in the 4th quarter worth about $26,000. United Financial Planning Group LLC purchased a new stake in shares of Stryker in the 3rd quarter valued at about $27,000. Atlas Capital Advisors Inc. bought a new stake in shares of Stryker during the 4th quarter valued at about $27,000. Finally, Gables Capital Management Inc. bought a new stake in shares of Stryker during the 2nd quarter valued at about $25,000. 77.09% of the stock is owned by institutional investors.

Stryker Stock Up 0.7%

Shares of NYSE SYK opened at $329.86 on Friday. The stock has a market capitalization of $126.52 billion, a P/E ratio of 34.18, a PEG ratio of 2.10 and a beta of 0.76. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86. The firm’s 50 day simple moving average is $326.99 and its two-hundred day simple moving average is $332.64. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same period in the previous year, the business posted $3.13 EPS. The business’s quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, analysts expect that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s payout ratio is currently 36.48%.

Insider Buying and Selling at Stryker

In other news, insider Debra King sold 826 shares of Stryker stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider owned 6,210 shares in the company, valued at approximately $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 665,370 shares of company stock worth $216,238,501 over the last three months. Company insiders own 4.60% of the company’s stock.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here’s Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Analyst Ratings Changes

SYK has been the topic of several research analyst reports. Citizens Jmp decreased their price objective on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a research report on Monday, August 3rd. Piper Sandler dropped their target price on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Robert W. Baird set a $385.00 price target on shares of Stryker in a research note on Friday, May 1st. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Finally, BTIG Research lowered their price objective on shares of Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.